期刊文献+

中西医综合疗法预防经皮冠状动脉介入治疗术后再狭窄的临床疗效分析 被引量:5

Clinical effect analysis of integrated traditional Chinese and western medicine therapy on the prevention of restenosis(RS) after percutaneous coronary intervention(PCI)
下载PDF
导出
摘要 目的:探讨中西医综合疗法预防经皮冠状动脉介入治疗(PCI)术后再狭窄(RS)的临床疗效。方法:选取2013年4月—2015年7月我院收治的68例行PCI术后的冠心病患者,随机分为对照组与观察组,每组34例,对照组给予常规药物治疗,观察组在对照组的基础上给予七味三芎汤。治疗6个月后,比较两组患者治疗总有效率、再狭窄发生率。结果:观察组的再狭窄发生率(2.9%)低于对照组(14.7%),具有统计学差异(P<0.05);观察组的治疗总有效率(97.1%)高于对照组(76.4%),具有统计学差异(P<0.05)。结论:中西医综合疗法可减少PCI术后RS的发生,安全有效,值得在临床上推广使用。 Objective: To explore the clinical effect of combined therapy of Chinese and Western Medicine on the prevention ofrestenosis (RS) after percutaneous coronary intervention (PCI). Methods: A total of 68 patients with coronary heart disease (CHD) after PCI,admitted to our hospital from April 2013 to July 2015, were randomized into the control group and the observation group, with 34 cases ineach group, the control group was given routine drug treatment while the observation group received Qiwei Sanqiong decoction on thebasis of the treatment of the control group. After 6 months’ treatment, the total effective rate and the incidence of restenosis of two groupswere compared. Results: The restenosis incidence of the observation group (2.9%) was lower than that of control group (14.7%), thedifference was of statistical significance (P<0.05); the total effective rate of the observation group (97.1%) was higher than that of thecontrol group (76.4%), the difference was of statistical significance (P<0.05). Conclusion: Integrated Traditional Chinese and Westernmedicine therapy could reduce the occurrence of RS after PCI, it was safe, effective, and was worthy of being popularized in clinicalapplication.
出处 《中医临床研究》 2016年第15期29-31,共3页 Clinical Journal Of Chinese Medicine
关键词 中西医综合 经皮冠状动脉介入治疗(PCI) 再狭窄(RS) 疗效 Integrated traditional Chinese and Western medicine Percutaneous coronary intervention (PCI) Restenosis (RS) Curative effect
  • 相关文献

参考文献4

二级参考文献36

  • 1黄洁,张梅英,刘利兵.PTCA后冠状动脉再狭窄的研究进展[J].医学争鸣,2001(S1):104-105. 被引量:3
  • 2中国血管病变早期检测技术应用指南制订委员会.中国血管病变早期检测技术应用指南(第一次报告).中国民康医学杂志,2006,18(5):323-331. 被引量:18
  • 3Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555. 被引量:1
  • 4Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651. 被引量:1
  • 5Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210. 被引量:1
  • 6Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13. 被引量:1
  • 7Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972. 被引量:1
  • 8Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932. 被引量:1
  • 9Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx. 被引量:1
  • 10Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243. 被引量:1

共引文献461

同被引文献57

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部